Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination nutraceutical containing **soy isoflavones** and **magnolia extract** is used primarily to alleviate vasomotor and psychoaffective symptoms in postmenopausal women. *Soy isoflavones* are phytoestrogens that can bind and modulate estrogen receptors, reducing the severity and frequency of hot flushes, night sweats, sleep disturbances, mood swings, and other menopausal symptoms. *Magnolia extract* (from Magnolia officinalis) contains biologically active compounds such as magnolol and honokiol, which exert anxiolytic, neurotrophic, and anti-inflammatory effects, likely through modulation of GABA-A receptors and enhancement of melatonin secretion. This combination is intended to synergize the estrogenic effects of isoflavones with the calming and sleep-promoting properties of magnolia, improving overall quality of life in postmenopausal women. Clinical studies indicate the combination is effective and well-tolerated, without adverse effects on mammary density, endometrial thickness, or liver function over 12 months[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on soy isoflavones + magnolia extract.